DZ2321A1 - Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant. - Google Patents

Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant.

Info

Publication number: DZ2321A1
Authority: DZ; Algeria
Prior art keywords: arylkylidene; lactams; aralkyl; processes; preparation
Prior art date: 1996-09-30

Application number

DZ970171A

Other languages

English (en)

Inventor

Harry Ralph Howard

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-30

Filing date

1997-09-29

Publication date

2002-12-28

1997-09-29 Application filed by Pfizer filed Critical Pfizer

2002-12-28 Application granted granted Critical

2002-12-28 Publication of DZ2321A1 publication Critical patent/DZ2321A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/06—Seven-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DZ970171A 1996-09-30 1997-09-29 Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant. DZ2321A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2711196P	1996-09-30	1996-09-30

Publications (1)

Publication Number	Publication Date
DZ2321A1 true DZ2321A1 (fr)	2002-12-28

Family

ID=21835752

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ970171A DZ2321A1 (fr)	1996-09-30	1997-09-29	Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant.

Country Status (45)

Country	Link
US (6)	US6380186B1 (fr)
EP (1)	EP0929528B1 (fr)
JP (1)	JP3121355B2 (fr)
KR (2)	KR100346620B1 (fr)
CN (2)	CN1093123C (fr)
AP (1)	AP769A (fr)
AR (1)	AR008861A1 (fr)
AT (1)	ATE245630T1 (fr)
AU (1)	AU732451B2 (fr)
BG (1)	BG64484B1 (fr)
BR (1)	BR9713239A (fr)
CA (1)	CA2266107C (fr)
CO (1)	CO4650135A1 (fr)
CZ (1)	CZ295141B6 (fr)
DE (1)	DE69723711T2 (fr)
DK (1)	DK0929528T3 (fr)
DZ (1)	DZ2321A1 (fr)
EA (1)	EA002157B1 (fr)
ES (1)	ES2202634T3 (fr)
GT (1)	GT199700107A (fr)
HN (1)	HN1997000135A (fr)
HR (1)	HRP970540B1 (fr)
ID (1)	ID19833A (fr)
IL (2)	IL140623A (fr)
IS (1)	IS4985A (fr)
MA (1)	MA26443A1 (fr)
MY (1)	MY125749A (fr)
NO (1)	NO313192B1 (fr)
NZ (1)	NZ334215A (fr)
OA (1)	OA11002A (fr)
PA (1)	PA8439101A1 (fr)
PE (1)	PE2799A1 (fr)
PL (1)	PL196005B1 (fr)
PT (1)	PT929528E (fr)
RS (1)	RS49699B (fr)
SA (2)	SA05260293B1 (fr)
SI (1)	SI0929528T1 (fr)
SK (1)	SK284704B6 (fr)
TN (1)	TNSN97161A1 (fr)
TR (1)	TR199900660T2 (fr)
TW (1)	TW491842B (fr)
UA (1)	UA56185C2 (fr)
UY (1)	UY24730A1 (fr)
WO (1)	WO1998014433A1 (fr)
ZA (1)	ZA978703B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6423708B1 (en) *	1996-09-30	2002-07-23	Pfizer Inc	Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) *	1996-09-30	2003-05-15	Пфайзер Інк.	Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US7189753B1 (en)	1997-11-06	2007-03-13	Cady Roger K	Preemptive prophylaxis of migraine
DE69919436T2 (de)	1998-04-16	2005-09-15	Pfizer Products Inc., Groton	N-Acyl und N-Aroyl Aralkylamide
HUP0201215A2 (en) *	1998-12-02	2002-08-28	Pfizer Prod Inc	Methods and compositions for restoring conformational stability of a protein of the p53 family
ATE277025T1 (de) *	1999-03-30	2004-10-15	Pfizer Prod Inc	Verfahren zur herstellung von cyclischen thioamiden
DE10022661A1 (de)	2000-05-10	2001-11-15	Clariant Gmbh	Ortho-substituierte Benzaldehyde, Verfahren zu ihrer Herstellung und ihre Verwendung
UA76130C2 (en)	2000-11-20	2006-07-17	Merck Patent Gmbh	Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
AU2002305123B2 (en) *	2001-03-30	2006-10-05	Philadelphia Health And Education Corporation	Immunomodulation and effect on cell processes relating to serotonin family receptors
EP1746091A1 (fr) *	2001-08-30	2007-01-24	Pfizer Products Inc.	Procédure pour la préparation du citrate 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one 2-substitué
PT1288208E (pt) *	2001-08-30	2006-09-29	Pfizer Prod Inc	Processo para preparacao de compostos de 2 - (4 - alquil - 1 - piperazinil) - benzaldeido e - benzilidenilo por substituicao necleofilica aromatica de 2 - fluorobenzaldeido com 4 - alquil - 1 - piperazina em agua como solvente
RU2270834C2 (ru) *	2001-12-07	2006-02-27	Пфайзер Продактс Инк.	Соль лимонной кислоты терапевтического соединения и фармацевтические композиции на ее основе
TW200301701A (en) *	2002-01-02	2003-07-16	Ardent Pharmaceuticals Inc	Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US7235573B2 (en)	2002-09-30	2007-06-26	The Regents Of The University Of California	Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
NZ538809A (en) *	2002-09-30	2008-06-30	Univ California	Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004033632A2 (fr) *	2002-10-04	2004-04-22	Bristol-Myers Squibb Company	Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace)
DE602004028150D1 (de) *	2003-11-26	2010-08-26	Pfizer Prod Inc	Aminopyrazolderivate als gsk-3-inhibitoren
WO2005053701A1 (fr) *	2003-11-26	2005-06-16	Pfizer Products Inc.	Association d'agonistes de la dopamine et d'imides et lactames heterocycliques d'aralkyle et d'aralkylidene
MXPA06006812A (es) *	2003-12-15	2006-08-23	Pfizer Prod Inc	Lactamas e imidas aralquilo y aralqulideno heterociclicas.
US20050171095A1 (en) *	2004-01-06	2005-08-04	Pfizer Inc	Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) *	2004-01-22	2005-07-28	Recordati Ireland Ltd.	Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
BRPI0507190A (pt) *	2004-01-29	2007-06-26	Pfizer Prod Inc	combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
ES2374629T3 (es) *	2004-03-17	2012-02-20	Pfizer Products Incorporated	Nuevos derivados de bencil(iden)-lactama.
AP2006003771A0 (en)	2004-04-30	2006-10-31	Warner Lambert Co	Substituted morpholine compounds for the treatmentof central nervous system disorders
BRPI0510942A (pt) *	2004-05-11	2007-07-17	Pfizer Prod Inc	combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
EP1753745A2 (fr) *	2004-05-21	2007-02-21	Pfizer Products Inc.	Derives pyrazinylmethyle-lactame
WO2005113526A2 (fr) *	2004-05-21	2005-12-01	Pfizer Products Inc.	Metabolites de 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
WO2006048727A1 (fr) *	2004-11-02	2006-05-11	Pfizer Products Inc.	Ligands de latame/amine piperazinylphenalkyle pour le recepteur 5ht1b
WO2006106416A1 (fr) *	2005-04-08	2006-10-12	Pfizer Products Inc.	Pyridil-lactams et leur utilisation comme ligands de recepteurs 5-ht1
WO2007026219A2 (fr) *	2005-08-31	2007-03-08	Pfizer Products Inc.	Composition d'antagonistes du recepteur 5-ht1b servant au traitement d'etats du systeme nerveux central
WO2007026224A2 (fr) *	2005-08-31	2007-03-08	Pfizer Products Inc.	Composition d'antagoniste 5-ht1b pour le traitement de la depression, de l'anxiete et des troubles de la cognition
WO2007057742A2 (fr) *	2005-11-18	2007-05-24	Pfizer Products Inc.	Nouveaux derives de piperazinone
GB0701970D0 (en) *	2007-02-01	2007-03-14	Wilson Stuart	Treatment of protein aggregation diseases
JP5647519B2 (ja)	2007-09-13	2014-12-24	コンサートファーマシューティカルズインコーポレイテッド	重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
MX2010010343A (es) *	2008-03-25	2010-10-15	Univ California	Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.
UY31952A (es)	2008-07-02	2010-01-29	Astrazeneca Ab	5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
WO2013050424A1 (fr) *	2011-10-03	2013-04-11	Euroscreen S.A.	Nouvelles n-acyl-5,6,7,8-tétrahydro[1,2,4]triazolo[4,3-a]pyrazines 8-substituées chirales utilisées comme antagonistes sélectifs des récepteurs nk-3, composition pharmaceutique, procédés destinés à être utilisés dans des troubles à médiation par le récepteur nk-3 et leur synthèse chirale
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
DE102013019618B4 (de) *	2013-11-25	2024-08-29	Avlen Georges	Tri- und Tetracyclische Verbindungen zur Behandlung von Inkontinenz
WO2020183011A1 (fr)	2019-03-14	2020-09-17	Institut Curie	Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
CN110054597B (zh) *	2019-04-17	2022-11-08	温州大学	一种无金属催化剂条件下合成的噻唑烷-4-酮衍生物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6229570A (ja)	1985-07-29	1987-02-07	Kanegafuchi Chem Ind Co Ltd	３，５−ジイソプロピルベンジリデン複素環式化合物
HU199134B (en)	1987-12-14	1990-01-29	Richter Gedeon Vegyeszet	Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
IE940525L (en) *	1988-05-25	1989-11-25	Warner Lambert Co	Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5216002A (en)	1989-12-21	1993-06-01	Eli Lilly And Company	Method of treating inflammatory bowel disease
DE4119757A1 (de) *	1991-06-15	1992-12-17	Basf Ag	Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
IL106142A (en) *	1992-06-29	1997-03-18	Merck & Co Inc	Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
ES2157256T3 (es) *	1993-03-16	2001-08-16	Pfizer	Derivados de naftaleno.
US5556841A (en)	1994-02-04	1996-09-17	Santen Pharmaceutical Co., Ltd.	Thiazine or thiomorpholine derivatives
GB9410512D0 (en)	1994-05-25	1994-07-13	Smithkline Beecham Plc	Novel treatment
JP3012338B2 (ja) *	1994-06-29	2000-02-21	ファイザーインク．	アリールおよびヘテロアリールアルコキシナフタレン誘導体
JP3852787B2 (ja)	1995-06-01	2006-12-06	久光製薬株式会社	チオモルホリン誘導体
EP0779282A1 (fr) *	1995-12-14	1997-06-18	Eli Lilly And Company	Dérivés de thiomorpholinone pour le traitement de la sclérose en plaques
CN1128788C (zh)	1996-03-29	2003-11-26	辉瑞大药厂	苄基(亚苄基)－内酰胺衍生物,它们的制备以及作为5－ht1a和/或5－ht1d受体的选择性拮抗剂(激动剂)的用途
UA56185C2 (uk) *	1996-09-30	2003-05-15	Пфайзер Інк.	Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) *	1996-09-30	2002-07-23	Pfizer Inc	Aralkyl and aralkylidene heterocyclic lactams and imides

1997
- 1997-08-09 UA UA99031735A patent/UA56185C2/uk unknown
- 1997-09-08 NZ NZ334215A patent/NZ334215A/xx unknown
- 1997-09-08 IL IL14062397A patent/IL140623A/xx not_active IP Right Cessation
- 1997-09-08 TR TR1999/00660T patent/TR199900660T2/xx unknown
- 1997-09-08 IL IL12904597A patent/IL129045A/xx not_active IP Right Cessation
- 1997-09-08 AT AT97936823T patent/ATE245630T1/de not_active IP Right Cessation
- 1997-09-08 PT PT97936823T patent/PT929528E/pt unknown
- 1997-09-08 WO PCT/IB1997/001062 patent/WO1998014433A1/fr not_active Ceased
- 1997-09-08 AU AU39514/97A patent/AU732451B2/en not_active Ceased
- 1997-09-08 ES ES97936823T patent/ES2202634T3/es not_active Expired - Lifetime
- 1997-09-08 PL PL97332629A patent/PL196005B1/pl not_active IP Right Cessation
- 1997-09-08 BR BR9713239-0A patent/BR9713239A/pt not_active Application Discontinuation
- 1997-09-08 DE DE69723711T patent/DE69723711T2/de not_active Expired - Lifetime
- 1997-09-08 CN CN97198344A patent/CN1093123C/zh not_active Expired - Fee Related
- 1997-09-08 RS YUP-168/99A patent/RS49699B/sr unknown
- 1997-09-08 EA EA199900242A patent/EA002157B1/ru not_active IP Right Cessation
- 1997-09-08 KR KR1020017005172A patent/KR100346620B1/ko not_active Expired - Fee Related
- 1997-09-08 SI SI9730562T patent/SI0929528T1/xx unknown
- 1997-09-08 KR KR1019997002707A patent/KR100323167B1/ko not_active Expired - Fee Related
- 1997-09-08 DK DK97936823T patent/DK0929528T3/da active
- 1997-09-08 JP JP10516337A patent/JP3121355B2/ja not_active Expired - Fee Related
- 1997-09-08 CN CNB011189541A patent/CN1239497C/zh not_active Expired - Fee Related
- 1997-09-08 CZ CZ19991071A patent/CZ295141B6/cs not_active IP Right Cessation
- 1997-09-08 SK SK410-99A patent/SK284704B6/sk unknown
- 1997-09-08 EP EP97936823A patent/EP0929528B1/fr not_active Expired - Lifetime
- 1997-09-08 CA CA002266107A patent/CA2266107C/fr not_active Expired - Fee Related
- 1997-09-18 US US09/254,999 patent/US6380186B1/en not_active Expired - Fee Related
- 1997-09-24 AP APAP/P/1997/001107A patent/AP769A/en active
- 1997-09-26 AR ARP970104457A patent/AR008861A1/es active IP Right Grant
- 1997-09-26 TW TW086114090A patent/TW491842B/zh not_active IP Right Cessation
- 1997-09-26 UY UY24730A patent/UY24730A1/es not_active IP Right Cessation
- 1997-09-26 MY MYPI97004484A patent/MY125749A/en unknown
- 1997-09-26 PE PE1997000864A patent/PE2799A1/es not_active Application Discontinuation
- 1997-09-29 DZ DZ970171A patent/DZ2321A1/fr active
- 1997-09-29 PA PA19978439101A patent/PA8439101A1/es unknown
- 1997-09-29 SA SA05260293A patent/SA05260293B1/ar unknown
- 1997-09-29 ZA ZA978703A patent/ZA978703B/xx unknown
- 1997-09-29 MA MA24815A patent/MA26443A1/fr unknown
- 1997-09-29 ID IDP973316A patent/ID19833A/id unknown
- 1997-09-29 TN TNTNSN97161A patent/TNSN97161A1/fr unknown
- 1997-09-29 GT GT199700107A patent/GT199700107A/es unknown
- 1997-09-29 SA SA97180449A patent/SA97180449B1/ar unknown
- 1997-09-30 HR HR970540A patent/HRP970540B1/xx not_active IP Right Cessation
- 1997-09-30 CO CO97056992A patent/CO4650135A1/es unknown
- 1997-11-23 HN HN1997000135A patent/HN1997000135A/es unknown
1999
- 1999-02-26 IS IS4985A patent/IS4985A/is unknown
- 1999-03-26 OA OA9900067A patent/OA11002A/en unknown
- 1999-03-29 NO NO19991525A patent/NO313192B1/no not_active IP Right Cessation
- 1999-03-30 BG BG103297A patent/BG64484B1/bg unknown
2001
- 2001-11-06 US US09/993,741 patent/US6627627B2/en not_active Expired - Fee Related
- 2001-11-06 US US10/011,505 patent/US6403592B1/en not_active Expired - Fee Related
- 2001-11-06 US US10/011,568 patent/US6921760B2/en not_active Expired - Fee Related
- 2001-11-06 US US09/994,027 patent/US6472388B2/en not_active Expired - Fee Related
2002
- 2002-03-06 US US10/091,963 patent/US6562813B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP3121355B2 (ja)	2000-12-25
GT199700107A (es)	1999-03-23
PA8439101A1 (es)	2000-05-24
EP0929528A1 (fr)	1999-07-21
PL196005B1 (pl)	2007-11-30
CZ107199A3 (cs)	2000-05-17
US6380186B1 (en)	2002-04-30
HK1022313A1 (en)	2000-08-04
ATE245630T1 (de)	2003-08-15
DE69723711D1 (de)	2003-08-28
PL332629A1 (en)	1999-09-27
YU16899A (sh)	2002-03-18
US20020072519A1 (en)	2002-06-13
DE69723711T2 (de)	2004-02-05
AU732451B2 (en)	2001-04-26
BG64484B1 (bg)	2005-04-30
US6403592B1 (en)	2002-06-11
US6627627B2 (en)	2003-09-30
SA97180449A (ar)	2005-12-03
TR199900660T2 (xx)	1999-07-21
ZA978703B (en)	1999-03-30
US20020147194A1 (en)	2002-10-10
NZ334215A (en)	2000-09-29
PT929528E (pt)	2003-12-31
AU3951497A (en)	1998-04-24
IS4985A (is)	1999-02-26
IL129045A (en)	2005-09-25
ES2202634T3 (es)	2004-04-01
EA199900242A1 (ru)	1999-08-26
CN1093123C (zh)	2002-10-23
AR008861A1 (es)	2000-02-23
RS49699B (sr)	2007-12-31
CA2266107A1 (fr)	1998-04-09
NO991525L (no)	1999-05-28
NO991525D0 (no)	1999-03-29
CA2266107C (fr)	2002-12-03
UA56185C2 (uk)	2003-05-15
US6562813B2 (en)	2003-05-13
ID19833A (id)	1998-08-06
KR100323167B1 (ko)	2002-02-04
HRP970540B1 (en)	2002-08-31
CN1231661A (zh)	1999-10-13
KR100346620B1 (ko)	2002-07-26
JP2000503679A (ja)	2000-03-28
US20020091118A1 (en)	2002-07-11
SK284704B6 (sk)	2005-09-08
OA11002A (en)	2001-11-06
TNSN97161A1 (fr)	2005-03-15
BG103297A (en)	1999-11-30
WO1998014433A1 (fr)	1998-04-09
DK0929528T3 (da)	2003-10-06
EP0929528B1 (fr)	2003-07-23
MY125749A (en)	2006-08-30
IL140623A (en)	2005-03-20
CN1329002A (zh)	2002-01-02
US6921760B2 (en)	2005-07-26
HN1997000135A (es)	1998-01-28
EA002157B1 (ru)	2001-12-24
AP9701107A0 (en)	1997-10-31
AP769A (en)	1999-09-30
CO4650135A1 (es)	1998-09-03
IL129045A0 (en)	2000-02-17
US6472388B2 (en)	2002-10-29
BR9713239A (pt)	2000-04-04
MA26443A1 (fr)	2004-12-20
IL140623A0 (en)	2002-02-10
US20020091119A1 (en)	2002-07-11
PE2799A1 (es)	1999-02-04
HRP970540A2 (en)	1998-08-31
TW491842B (en)	2002-06-21
NO313192B1 (no)	2002-08-26
SK41099A3 (en)	2000-09-12
KR20000048731A (ko)	2000-07-25
CZ295141B6 (cs)	2005-05-18
UY24730A1 (es)	2000-09-29
SA97180449B1 (ar)	2005-12-21
SI0929528T1 (en)	2003-10-31
SA05260293B1 (ar)	2006-04-18
US20020091117A1 (en)	2002-07-11
CN1239497C (zh)	2006-02-01

Publication	Publication Date	Title
DZ2321A1 (fr)	2002-12-28	Aralkyl-et arylkylidène-lactames et -imides hétér ocycliques procédés pour leur préparation et compositions pharamceutiques les contenant.
DZ2465A1 (fr)	2003-01-18	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
MA23866A1 (fr)	1996-12-31	N-(indole-2-carbonyl)-glycinamides substitues, procede pour leur preparation et compositions les contenant
DZ1958A1 (fr)	2002-02-17	Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2358A1 (fr)	2002-12-28	Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2172A1 (fr)	2002-12-01	Dérivés de triazole utiles on thérapeutique, procédé pour leur préparation et compositions les contenant.
DZ2745A1 (fr)	2003-09-08	BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA24158A1 (fr)	1997-12-31	Derives d'imidazole substitues, procede pour leur preparation et compositions les contenant
DZ2360A1 (fr)	2002-12-28	Dérivés de pyrazole procédé pour leur préparation et compositions les contenant
FR2714848B1 (fr)	1996-11-15	Microcapsules et procédés pour leur préparation.
MA26526A1 (fr)	2004-12-20	Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2729951B1 (fr)	1997-04-18	Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
EP0718287A3 (fr)	1997-01-29	Dérivés de pipérazine, médicaments les contenant, leur application, et procédés pour leur préparation
DZ2045A1 (fr)	2002-07-21	Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26490A1 (fr)	2004-12-20	Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
DZ2188A1 (fr)	2002-12-02	Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
DZ2155A1 (fr)	2002-10-26	Aazétidines, procédé pour leur préparation, et co mpositions pharmaceutiques les contenant.